Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion The final bid, at $10 billion, is expected to wrap up after Nov. 13 with the next shareholders' vote.
Monday's pre-market session: top gainers and losers The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Novo Nordisk Loses Metsera Bidding War To Pfizer — But Retail Traders Aren’t Losing Faith Novo investors on Stocktwits praised new CEO Mike Doustdar as “dynamic,” saying they remain confident in Novo’s long-term obesity and diabetes pipeline despite short-term setbacks.
Pfizer Clinches $10 Billion Deal To Buy Obesity Drug Maker Metsera, Outbidding Novo Nordisk In Fierce Battle For Weight-Loss Market Dominance Nvidia CEO Jensen Huang cautioned Elon Musk against underestimating the challenges of semiconductor manufacturing, saying building a chip fab like TSMC's is "extremely hard."
The Weight-Loss Drugs Craze Is Going Strong. But Stock Investors Should Know A Few Things. The feast that saw obesity-tied stocks skyrocket in 2024 is over. Investors' appetite for weight-loss drugs has waned.
Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal Delaware court denies Pfizer bid to block Metsera's Novo Nordisk deal as FTC flags antitrust risks and Pfizer prepares a higher counteroffer.
Novo Nordisk Reportedly Refrains From Backing Down In Metsera Acquisition Battle, Sweetens Bid Further According to an FT report, Pfizer now has two days to match Novo’s new bid or let its agreed-upon deal with Metsera fall through.
'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.
Novo Nordisk Snaps 11-Day Losing Streak After Court Rejects Pfizer’s Challenge To $10B Metsera Deal Delaware Chancery Judge Morgan Zurn ruled that Pfizer’s objections did not justify delaying Novo’s $10 billion acquisition of obesity-drug startup Metsera.
Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.
Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.
Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.
Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.
Did Novo Nordisk Just Say "Checkmate" to Pfizer? These two leading drugmakers are fighting over a promising GLP-1 candidate.
